drugset
drugset / Trial / NCT03425539

Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease

NCT03425539 ↗

Phase 3 Completed 118 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aimed to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease.

Timeline

Start
2018-06-21
Primary completion
2021-08-17
Completion
2021-09-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Lucerastat Small molecule 1000 mg Oral

Indications

Fabry disease